Hood River Capital Management LLC grew its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) by 2.3% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 165,102 shares of the biotechnology company’s stock after buying an additional 3,680 shares during the quarter. Ligand Pharmaceuticals accounts for 1.4% of Hood River Capital Management LLC’s investment portfolio, making the stock its 24th biggest position. Hood River Capital Management LLC owned 0.84% of Ligand Pharmaceuticals worth $22,479,000 as of its most recent filing with the SEC.
Other institutional investors also recently bought and sold shares of the company. Strs Ohio raised its position in shares of Ligand Pharmaceuticals by 225.0% during the 2nd quarter. Strs Ohio now owns 1,300 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 900 shares in the last quarter. First Mercantile Trust Co. raised its position in shares of Ligand Pharmaceuticals by 1.6% during the 2nd quarter. First Mercantile Trust Co. now owns 1,310 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 20 shares in the last quarter. Harbor Advisors LLC purchased a new stake in shares of Ligand Pharmaceuticals during the 3rd quarter valued at $204,000. Round Table Services LLC purchased a new stake in shares of Ligand Pharmaceuticals during the 3rd quarter valued at $205,000. Finally, Teacher Retirement System of Texas purchased a new stake in shares of Ligand Pharmaceuticals during the 2nd quarter valued at $203,000.
Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) traded down $0.72 during trading hours on Thursday, reaching $144.35. 255,600 shares of the company were exchanged, compared to its average volume of 247,377. The stock has a market cap of $3,061.77, a PE ratio of 109.07, a PEG ratio of 2.24 and a beta of 0.94. Ligand Pharmaceuticals Incorporated has a one year low of $95.08 and a one year high of $149.31. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.95 and a current ratio of 0.97.
Ligand Pharmaceuticals (NASDAQ:LGND) last issued its earnings results on Thursday, November 9th. The biotechnology company reported $0.69 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.32. The company had revenue of $33.38 million for the quarter, compared to analysts’ expectations of $31.04 million. Ligand Pharmaceuticals had a net margin of 12.76% and a return on equity of 7.83%. The firm’s revenue was up 54.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.62 EPS. equities research analysts predict that Ligand Pharmaceuticals Incorporated will post 2.35 EPS for the current fiscal year.
Several analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Ligand Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $165.00 price objective on the stock in a research report on Thursday, October 12th. BidaskClub cut shares of Ligand Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Stephens restated an “overweight” rating and set a $137.00 price objective (up previously from $125.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday, August 9th. Craig Hallum restated a “buy” rating and set a $170.00 price objective (up previously from $160.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday. Finally, Deutsche Bank AG raised their price objective on shares of Ligand Pharmaceuticals from $103.00 to $104.00 and gave the company a “hold” rating in a research report on Tuesday, August 8th. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $148.83.
In related news, Director Jason Aryeh sold 2,000 shares of Ligand Pharmaceuticals stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $127.99, for a total value of $255,980.00. Following the transaction, the director now owns 59,625 shares in the company, valued at approximately $7,631,403.75. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO John L. Higgins sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $130.00, for a total transaction of $650,000.00. Following the completion of the transaction, the chief executive officer now owns 144,171 shares in the company, valued at approximately $18,742,230. The disclosure for this sale can be found here. 14.70% of the stock is owned by company insiders.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND).
Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.